BR9800766A - Combination preparation for application in dementia. - Google Patents

Combination preparation for application in dementia.

Info

Publication number
BR9800766A
BR9800766A BR9800766-1A BR9800766A BR9800766A BR 9800766 A BR9800766 A BR 9800766A BR 9800766 A BR9800766 A BR 9800766A BR 9800766 A BR9800766 A BR 9800766A
Authority
BR
Brazil
Prior art keywords
dementia
application
combination preparation
compound
combination
Prior art date
Application number
BR9800766-1A
Other languages
Portuguese (pt)
Inventor
Karl Rudolphi
Hildegard Nimmesgern
Hans-Peter Schubert
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of BR9800766A publication Critical patent/BR9800766A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Patente de Invenção: <B>"PREPARADO DE COMBINAçãO PARA A APLICAçãO NA DEMêNCIA"<D>. Um preparado de combinação, contendo um composto, que apresenta um efeito inibidor de acetilcolinesterase ou mostra efeito muscarinérgico e um composto, que aumenta o nível de adenosina extracelular endógeno, presta-se para o tratamento da demência.Invention Patent: <B> "PREPARED FOR COMBINATION FOR DEMAND APPLICATION" <D>. A combination preparation containing a compound that has an acetylcholinesterase inhibitory effect or shows a muscarinergic effect and a compound that increases the level of endogenous extracellular adenosine is suitable for the treatment of dementia.

BR9800766-1A 1997-02-26 1998-02-25 Combination preparation for application in dementia. BR9800766A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19707655A DE19707655A1 (en) 1997-02-26 1997-02-26 Combination preparation for use in dementia

Publications (1)

Publication Number Publication Date
BR9800766A true BR9800766A (en) 1999-12-07

Family

ID=7821517

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9800766-1A BR9800766A (en) 1997-02-26 1998-02-25 Combination preparation for application in dementia.

Country Status (30)

Country Link
US (1) US6037347A (en)
EP (1) EP0867192B1 (en)
JP (1) JP4374440B2 (en)
KR (1) KR100517186B1 (en)
CN (1) CN100363005C (en)
AR (1) AR011860A1 (en)
AT (1) ATE295738T1 (en)
AU (1) AU749278C (en)
BR (1) BR9800766A (en)
CA (1) CA2230350C (en)
CZ (1) CZ298367B6 (en)
DE (2) DE19707655A1 (en)
DK (1) DK0867192T3 (en)
EE (1) EE03387B1 (en)
ES (1) ES2242243T3 (en)
HR (1) HRP980097B1 (en)
HU (1) HUP9800396A3 (en)
ID (1) ID19941A (en)
IL (1) IL123453A (en)
MY (1) MY120530A (en)
NO (1) NO327200B1 (en)
NZ (1) NZ329839A (en)
PL (1) PL191576B1 (en)
PT (1) PT867192E (en)
RU (1) RU2194508C2 (en)
SI (1) SI0867192T1 (en)
SK (1) SK284925B6 (en)
TR (1) TR199800302A3 (en)
TW (1) TW590772B (en)
ZA (1) ZA981561B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237163T3 (en) * 1998-10-01 2005-07-16 Novartis Ag NEW ORAL FORMULATIONS OF REVASTIGMINE CONTROLLED LIBERATION.
US20040110776A1 (en) * 2002-02-22 2004-06-10 Iok-Hou Pang Use of propentofylline to control intraocular pressure
US20040092427A1 (en) * 2002-09-25 2004-05-13 Anil Gulati Method and composition for treating alzheimer's disease and dementias of vascular origin
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
EP1830886B1 (en) 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
CN101166543B (en) * 2005-04-28 2014-07-16 卫材R&D管理有限公司 Composition containing antidementia agent
WO2017044693A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
RU2616247C1 (en) * 2016-03-28 2017-04-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинский государственный университет имени Коста Левановича Хетагурова" (СОГУ) Solid dosage forms with choline-positive action based on 9-butylamino-3,3-dimethyl-1,2,4-trihydroacridine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737433A (en) * 1964-09-05 1973-06-05 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines
US3621096A (en) * 1969-04-03 1971-11-16 Univ North Carolina Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
DE2330742C2 (en) * 1973-06-16 1982-07-29 Hoechst Ag, 6000 Frankfurt 1- (Oxoalkyl) -3-methyl-7-alkylxanthines, process for their preparation and pharmaceuticals containing them
DE2856393C2 (en) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Medicines used to treat Parkinson's disease
JPH062675B2 (en) * 1985-04-05 1994-01-12 ヘキストジヤパン株式会社 Memory disorder treatment
DE3525801A1 (en) * 1985-07-19 1987-01-22 Hoechst Ag TERTIA HYDROXYALKYLXANTHINE, METHOD FOR THE PRODUCTION THEREOF, THE MEDICINAL PRODUCT CONTAINING IT AND THEIR USE
IL81610A (en) * 1986-02-27 1990-12-23 Roussel Uclaf Derivatives of 1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime,their preparation and pharmaceutical compositions containing them
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
FI95572C (en) * 1987-06-22 1996-02-26 Eisai Co Ltd Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt
IL87861A0 (en) * 1987-10-05 1989-03-31 Pfizer 4-aminopyridine derivatives
WO1989002739A1 (en) * 1987-10-05 1989-04-06 Pfizer Inc. 4-aminopyridine derivatives
DE3817955A1 (en) * 1988-05-27 1989-11-30 Hoechst Ag MEDICINAL PRODUCT CONTAINING TNF INHIBITOR
WO1991004032A1 (en) * 1989-09-15 1991-04-04 Gensia Pharmaceuticals, Inc. Methods of treating neurodegenerative conditions
DE4236331A1 (en) * 1992-10-28 1994-05-05 Boehringer Ingelheim Kg Synergistic combination
US5783584A (en) * 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment

Also Published As

Publication number Publication date
HRP980097B1 (en) 2006-09-30
HRP980097A2 (en) 1998-12-31
US6037347A (en) 2000-03-14
CZ54098A3 (en) 1998-09-16
CZ298367B6 (en) 2007-09-12
NO327200B1 (en) 2009-05-11
HUP9800396A1 (en) 1999-07-28
PL191576B1 (en) 2006-06-30
TR199800302A2 (en) 1998-09-21
NZ329839A (en) 2000-05-26
SK284925B6 (en) 2006-02-02
ID19941A (en) 1998-08-27
AU749278C (en) 2003-07-31
IL123453A0 (en) 1998-09-24
EP0867192A3 (en) 2000-12-06
CN1192904A (en) 1998-09-16
CN100363005C (en) 2008-01-23
TW590772B (en) 2004-06-11
EE9800075A (en) 1998-10-15
KR100517186B1 (en) 2005-12-05
TR199800302A3 (en) 1998-09-21
CA2230350C (en) 2007-07-24
SK24098A3 (en) 1998-09-09
AU749278B2 (en) 2002-06-20
RU2194508C2 (en) 2002-12-20
ATE295738T1 (en) 2005-06-15
CA2230350A1 (en) 1998-08-26
MY120530A (en) 2005-11-30
HU9800396D0 (en) 1998-04-28
DK0867192T3 (en) 2005-09-05
DE19707655A1 (en) 1998-08-27
EP0867192B1 (en) 2005-05-18
HUP9800396A3 (en) 2001-05-28
MX9801515A (en) 1998-08-30
AU5627398A (en) 1998-09-03
NO980786D0 (en) 1998-02-25
PT867192E (en) 2005-08-31
IL123453A (en) 2004-06-20
ES2242243T3 (en) 2005-11-01
AR011860A1 (en) 2000-09-13
SI0867192T1 (en) 2005-10-31
KR19980071717A (en) 1998-10-26
PL325074A1 (en) 1998-08-31
JP4374440B2 (en) 2009-12-02
EP0867192A2 (en) 1998-09-30
EE03387B1 (en) 2001-04-16
JPH10236979A (en) 1998-09-08
DE59812801D1 (en) 2005-06-23
NO980786L (en) 1998-08-27
ZA981561B (en) 1998-08-26

Similar Documents

Publication Publication Date Title
BG104247A (en) Resorcinol derivatives
BR9808932A (en) Process to prevent an inflammation-related cardiovascular disorder
ES2195970T3 (en) L-RIBAVIRINA AND USES OF THE SAME.
EP0935963A3 (en) The use of MMP-13 selective inhibitors for the treatment of osteoarthritis and other matrix metalloproteinase-mediated disorders
BR9814040A (en) Acute lung with fibrosis with avb6 antagonists
ATE423562T1 (en) ALPHA-KETOAMID CONTAINING MULTICATALYTIC PROTEASE INHIBITORS
BR9913705A (en) Methods for the treatment of multiple myeloma and bone tissue resorption induced by myeloma using integrin antagonists
BR9800766A (en) Combination preparation for application in dementia.
PT1032414E (en) COMBINATION OF AN INHIBITOR OF THE ANGIOTENSIN CONVERSATION ENZYME AND A DIURETIC FOR THE TREATMENT OF MICROCIRCULATORY DISTURBACTIONS
AR002253A1 (en) Compound derived from phenyl-alkanol biocide containing composition and processes to produce it
CA2284142A1 (en) Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
BR9604818A (en) Combination compositions containing benazepril or benazeprilat and valsartan
ATE188869T1 (en) STABILIZED SUNSCREEN
DK0743060T3 (en) Use of dentifrices containing bovine colostrum
ES2172682T3 (en) DEODORANT PREPARATIONS WITH CONTENT IN QUITOSANE, ALUMINUM CHLOROHIDRATE AND ESTERASE INHIBITORS.
DE975695T1 (en) COMPOSITIONS CONTAINING LUBRICANTS AND ANTIBLOCKING AGENTS
ES2186807T3 (en) THROMBIN INHIBITORS.
BR9712307A (en) Pyrazolinones for the treatment of weakened potency
BG104292A (en) Methods and compositions for the treatment of rheumatoid arthritis
BR9810481A (en) Process for the preparation of 4-substituted 1h-indole-3-glyoxamides.
GT199900087A (en) COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY.
AU6849198A (en) Neurotrypsin
FI962979A0 (en) Pharmaceutical compositions containing hirudin
FR2763842B1 (en) COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS CONTAINING THREONINE OR SERINE DERIVATIVES
BR9907697A (en) Serine carbonates

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O C/C ART. 13 DA LPI )

B12B Appeal against refusal [chapter 12.2 patent gazette]